New Directions In STD Treatment - University of Hawaii

More documents

Recommendations

Info

Syphilis Issues � Diagnostic issues � Criteria for diagnosing early latent is change to be consistent with the surveillance case definition � New EIA testing algorithms: � reflexive quantitative RPR/VDRL � alternative treponemal test for discrepancies � FP in low risk populations � Some experts recommend CSF exam for � All patients with latent syphilis and RPR ≥ 1:32 � HIV-infected patients with latent syphilis and CD4 count ≤ 350 � Recommend against the use of azithromycin � Note penicillin usage problems � BIC shortage � Specify use of Bicillin L-A (NOT Bicillin C-R)
Latent Syphilis � No clinical manifestations: only evidence is positive serologic tests � Divided into two stages for treatment purposes �Early latent syphilis: 1yr duration * Could be treatment failure
Page 1 and 2: New Directions in STD Treatment: Hi
Page 3 and 4: CDC 2006 STD Treatment Guidelines D
Page 5 and 6: Challenging Management Dilemmas in
Page 7 and 8: Sexual History Taking: The 5 P’s
Page 9 and 10: Recommend Nucleic Acid Amplificatio
Page 11 and 12: Percent Screened Estimated Chlamydi
Page 13 and 14: STD Screening for MSM STD Site Type
Page 15 and 16: Prevalence of rectal chlamydia and
Page 17 and 18: Prevalence of pharyngeal chlamydia
Page 19 and 20: C. trachomatis NAAT Testing …not
Page 21 and 22: Chlamydia Treatment in Pregnancy Re
Page 23 and 24: Percent 16 14 12 10 Infection Durin
Page 25 and 26: Provider Barriers to PDPT, CA 2002
Page 27 and 28: Gonorrhea Screening in Females �
Page 29 and 30: Percent of Neisseria gonorrhoeae Is
Page 31 and 32: Gonorrhea Treatment of Urogenital I
Page 33 and 34: Lymphogranuloma Venereum (LGV) C. t
Page 35 and 36: LGV Proctocolitis: Serologic Diagno
Page 37 and 38: Phil and the Penis on the Go
Page 39: The Three “R”s of Syphilis �
Page 43 and 44: Syphilis EIA Tests �Treponemal te
Page 45 and 46: Criteria for CSF Examination � Ne
Page 47 and 48: Syphilis Resistant to Azithromycin!
Page 51 and 52: HSV Issues � Role of type-specifi
Page 53 and 54: Rates of Transmission of HSV-2 to S
Page 55 and 56: Genital Herpes - Treatment Issues
Page 57 and 58: HPV Issues � Clarify uses of HPV
Page 59 and 60: Issues Regarding Anal Cancer Screen
Page 61 and 62: Cervicitis - Diagnostic Issues �
Page 63 and 64: Pelvic Inflammatory Disease Issues
Page 65 and 66: PID: Oral Treatment Regimens Oral r
Page 67 and 68: Vaginitis Trichomonas Bacterial Vag
Page 69 and 70: Tinidazole: A New Treatment Option
Page 71 and 72: Proposed Management Trichomoniasis
Page 73 and 74: BV Treatment Recommended regimens:
Page 75: STD Resources California STD/HIV Pr

New Directions In STD Treatment - University of Hawaii

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?